Cargando…
104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()()
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sociedade Brasileira de Dermatologia
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790214/ https://www.ncbi.nlm.nih.gov/pubmed/34593266 http://dx.doi.org/10.1016/j.abd.2020.08.030 |
| _version_ | 1784639945703424000 |
|---|---|
| author | Pereyra-Rodriguez, Jose Juan Dominguez-Cruz, Javier Armario-Hita, Jose Carlos Ruiz-Villaverde, Ricardo |
| author_facet | Pereyra-Rodriguez, Jose Juan Dominguez-Cruz, Javier Armario-Hita, Jose Carlos Ruiz-Villaverde, Ricardo |
| author_sort | Pereyra-Rodriguez, Jose Juan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8790214 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Sociedade Brasileira de Dermatologia |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87902142022-02-01 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()() Pereyra-Rodriguez, Jose Juan Dominguez-Cruz, Javier Armario-Hita, Jose Carlos Ruiz-Villaverde, Ricardo An Bras Dermatol Research Letter Sociedade Brasileira de Dermatologia 2021 2021-09-27 /pmc/articles/PMC8790214/ /pubmed/34593266 http://dx.doi.org/10.1016/j.abd.2020.08.030 Text en © 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Research Letter Pereyra-Rodriguez, Jose Juan Dominguez-Cruz, Javier Armario-Hita, Jose Carlos Ruiz-Villaverde, Ricardo 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()() |
| title | 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()() |
| title_full | 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()() |
| title_fullStr | 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()() |
| title_full_unstemmed | 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()() |
| title_short | 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()() |
| title_sort | 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. the experience of 5 reference dermatology units in spain()() |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790214/ https://www.ncbi.nlm.nih.gov/pubmed/34593266 http://dx.doi.org/10.1016/j.abd.2020.08.030 |
| work_keys_str_mv | AT pereyrarodriguezjosejuan 104weeksafetyandeffectivenessofdupilumabinthetreatmentofsevereatopicdermatitistheexperienceof5referencedermatologyunitsinspain AT dominguezcruzjavier 104weeksafetyandeffectivenessofdupilumabinthetreatmentofsevereatopicdermatitistheexperienceof5referencedermatologyunitsinspain AT armariohitajosecarlos 104weeksafetyandeffectivenessofdupilumabinthetreatmentofsevereatopicdermatitistheexperienceof5referencedermatologyunitsinspain AT ruizvillaverdericardo 104weeksafetyandeffectivenessofdupilumabinthetreatmentofsevereatopicdermatitistheexperienceof5referencedermatologyunitsinspain |